In recent years, many small molecule inhibitors targeting PI3K, AKT, and the downstream effector mTOR have been developed; several are in clinical trials, and some have been approved for therapy by FDA, of which idelalisib has been approved for the treatment of relapsed chronic lymphocytic leukemia (CLL), relapsed follicular B-cell non-Hodgkin’s lymphoma (FL), and relapsed small lymphocytic lymphoma (SLL)9 and Everolimus is approved in combination with exemestane to treat postmenopausal women with advanced hormone receptor positive, HER2-negative breast cancer10. Here, AKT1 is linked to B-cell chronic lymphocytic leukemia.